



EUROPEAN COMMISSION  
DG Competition

***Case M.8556 - CARLYLE / GTCR / ALBANY MOLECULAR  
RESEARCH***

Only the English text is available and authentic.

**REGULATION (EC) No 139/2004  
MERGER PROCEDURE**

---

Article 6(1)(b) NON-OPPOSITION  
Date: 16/08/2017

***In electronic form on the EUR-Lex website under document  
number 32017M8556***



EUROPEAN COMMISSION

Brussels, 16.8.2017  
C(2017) 5777 final

PUBLIC VERSION

**To the notifying parties:**

**Subject: Case M. 8556 – CARLYLE / GTCR / ALBANY MOLECULAR RESEARCH  
Commission decision pursuant to Article 6(1)(b) of Council Regulation (EC)  
No 139/2004<sup>1</sup> and Article 57 of the Agreement on the European Economic Area<sup>2</sup>**

Dear Sir or Madam,

1. On 17 July 2017, the European Commission received notification of a proposed concentration pursuant to Article 4 of the Merger Regulation by which The Carlyle Group ('Carlyle', United States) and GTCR LLC ('GTCR', United States) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Albany Molecular Research, Inc. ('AMRI', United States) by way of a purchase of shares.<sup>3</sup>
2. The business activities of the undertakings concerned are:
  - **for Carlyle:** global alternative asset manager, which manages funds that invest globally across four investment disciplines: corporate private equity; real assets; global market strategies; and solutions,
  - **for GTCR:** private equity firm founded focused on investing in growth companies in the financial services and technology, healthcare, technology, media and telecommunications and growth business services industries,

---

<sup>1</sup> OJ L 24, 29.1.2004, p. 1 (the 'Merger Regulation'). With effect from 1 December 2009, the Treaty on the Functioning of the European Union ('TFEU') has introduced certain changes, such as the replacement of 'Community' by 'Union' and 'common market' by 'internal market'. The terminology of the TFEU will be used throughout this decision.

<sup>2</sup> OJ L 1, 3.1.1994, p. 3 (the 'EEA Agreement').

<sup>3</sup> Publication in the Official Journal of the European Union No C 240, 25/07/2017, p. 13.

- **for AMRI:** global contract research and manufacturing organization providing customers integrated drug discovery, development, and manufacturing services
3. After examination of the notification, the European Commission has concluded that the notified operation falls within the scope of the Merger Regulation and of paragraph 5(c) of the Commission Notice on a simplified procedure for treatment of certain concentrations under Council Regulation (EC) No 139/2004.<sup>4</sup>
  4. For the reasons set out in the Notice on a simplified procedure, the European Commission has decided not to oppose the notified operation and to declare it compatible with the internal market and with the EEA Agreement. This decision is adopted in application of Article 6(1)(b) of the Merger Regulation and Article 57 of the EEA Agreement.

*For the Commission*

*(Signed)*

*Johannes LAITENBERGER  
Director-General*

---

<sup>4</sup> OJ C 366, 14.12.2013, p. 5.